Latest Buprenorphine Stories
Developers of Clarity™ Intensive Outpatient Opiate Treatment Announce Undergraduate and Graduate Scholarships for Students of Evidence-Based Addiction Medicine West
Oral Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Sublingual and Intravenous Formulations NEW YORK, April 21, 2015 /PRNewswire/ -- Relmada Therapeutics,
Phase 1 study to include additional cohorts with novel product candidate being developed for the treatment of neuropathic pain NEW YORK, April 16, 2015 /PRNewswire/ -- Relmada Therapeutics,
SALT LAKE CITY, April 8, 2015 /PRNewswire/ -- Phoenix PharmaLabs, Inc.
Programs encouraging appropriate use of painkillers could improve safety, reduce costs ST.
While many healthcare professionals continue to advocate in favor of methadone treatment for heroin addiction, a new survey reveals that half of Americans agree with Novus Medical Detox Center
Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations NEW YORK, March 24, 2015 /PRNewswire/ -- Relmada
A new form of Naltrexone, Vivitrol, has been proven effective in treating nearly every patient prescribed the opiate blocking medication by the Washington County Health Department, according to
Harbor Village Detox comments on the effectiveness of naltrexone, which is a non opiate based drug helping drug addicts to overcome heroin addiction and opiate abuse.
Novel product candidate being developed for the treatment of neuropathic pain demonstrates good safety profile even at higher doses NEW YORK, March 17, 2015 /PRNewswire/ -- Relmada
- A person in a secondary role, specifically the second most important character (after the protagonist).